Research Topics
Species | Ramesh K RamanathanSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancerShelley Dranko
University of Pittsburgh Cancer Institute, PA, USA
Clin Colorectal Cancer 6:224-5. 2006..Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed...- Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 57:465-74. 2006..The pharmacokinetics of MGd were also evaluated... - A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancerRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 61:453-8. 2008..Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC... - Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Cancer Chemother Pharmacol 55:354-60. 2005..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination... - Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
Clin Cancer Res 13:1769-74. 2007..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week... 
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741Hanna K Sanoff
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
J Clin Oncol 26:5721-7. 2008....
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam
Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Clin Cancer Res 14:3456-61. 2008..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...- Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsLaura L Jung
Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
Cancer Chemother Pharmacol 54:487-96. 2004..97, respectively. The recovery of 9NC and 9AC in the urine was <15%. CONCLUSIONS: There was significant interpatient and intrapatient variability in the disposition of 9NC and 9AC. 9NC and 9AC undergo primarily nonrenal elimination... - Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni
Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Clin Cancer Res 10:5058-64. 2004..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration... - Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan
Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
Clin Cancer Res 11:3385-91. 2005..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics... - Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman
Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
Clin Cancer Res 13:2121-7. 2007..Pretreatment plasma samples were also obtained from 12 healthy volunteers. Plasma IGFBP-2 and Her-2 ECD concentrations were quantitated by ELISA... - Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignanciesSuresh S Ramalingam
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Clin Cancer Res 13:3605-10. 2007..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel... - Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan
Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Clin Oncol 28:1520-6. 2010..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)... - Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumorsAbdulateef O Aregbe
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 W 10th Street, WD W7123, Indianapolis, IN 46202, USA
Cancer Chemother Pharmacol 70:201-5. 2012..To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis... - Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancerBenedito A Carneiro
University of Pittsburgh Cancer Institute, PA 15232, USA
Clin Colorectal Cancer 11:53-9. 2012..Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC... - Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesWilliam C Zamboni
Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Invest New Drugs 24:393-401. 2006..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC... - The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Oncologist 12:38-50. 2007.... - A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancerRajesh Sehgal
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Clin Colorectal Cancer 10:117-20. 2011..A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)... - Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapyHitendra Patel
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA 15213, USA
Invest New Drugs 24:359-63. 2006..1-12.6) months, and median time to progression was 2.1 months. CONCLUSIONS: Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC... - Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
Cancer Invest 22:858-65. 2004.... - A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancerKhalid Matin
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Am J Clin Oncol 28:439-44. 2005..9 months (95% CI, 5.2-10.2 months). CONCLUSIONS: The combination of TMTX and CAP is well tolerated. However, recent studies have shown more active regimens in the second- and third-line metastatic setting... - Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humansSakkaraiappan Ramalingam
Divison of Hemotology/Oncology, Deparatment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Pharmacotherapy 24:1232-5. 2004..8% of the daily dose and CGP 74588 accounted for 0.2%. These data show both the qualitative similarities and the quantitative variability in biliary excretion of imatinib and its principal metabolite... - A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Cancer Chemother Pharmacol 64:777-83. 2009..To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC)... - A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancerRamesh K Ramanathan
University of Pittsburgh Cancer Institute, PA, USA
Clin Colorectal Cancer 7:134-9. 2008..This randomized, multicenter phase II trial was designed to evaluate and compare the efficacy of 4 different oxaliplatin/5-FU regimens... - A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Clin Cancer Res 13:2109-14. 2007..Objectives of this study were to determine safety, tolerability, pharmacodynamics, and pharmacokinetics of PX-12, a small-molecule inhibitor of Trx-1... - Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinomaMace L Rothenberg
Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
J Clin Oncol 23:9265-74. 2005..Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha)... - Update for surgeons: recent and noteworthy changes in therapeutic regimens for cancer of the colon and rectumClaudia Hriesik
Department of Surgery, Division of Surgical Oncology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15261, USA
J Am Coll Surg 205:468-78 (Quiz 524). 2007 - A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerRichard M Goldberg
Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
J Clin Oncol 22:23-30. 2004..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease... - Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a caseShelly S Lo
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
Dis Colon Rectum 48:1316-9. 2005..Current studies are underway that may help us optimize the treatment for patients with gastrointestinal stromal tumors... - Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07J Philip Kuebler
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
J Clin Oncol 25:2198-204. 2007..This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer... - Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasmaRobert A Parise
Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, 15213, Pittsburgh, PA, USA
J Chromatogr B Analyt Technol Biomed Life Sci 783:231-6. 2003..The LC-MS assay, which proved superior because of its greater sensitivity and relatively short (7 min) run time, should be an important tool for future pharmacokinetic analyses of docetaxel and paclitaxel... - 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I studyFiras N Shadad
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, PA 15232, USA
Clin Lymphoma Myeloma 6:500-1. 2006 - Treatment of colon and rectal cancerDavid Blumberg
Division of GI Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15261, USA
J Clin Gastroenterol 34:15-26. 2002..This review details many of these advances in a comprehensive manner and illustrates the necessity of a multidisciplinary approach for optimizing outcome for patients with these cancers... - Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenograftsWilliam C Zamboni
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213 1863, USA
Clin Cancer Res 11:4867-74. 2005..These results suggest that the intermittent schedule of 9-nitrocamptothecin may be an active regimen in patients with colorectal carcinoma... - Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
J Clin Oncol 21:2904-11. 2003.... - HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinomaSaima Sharif
Allegheny Cancer Center, Pittsburgh, PA, USA
Dig Dis Sci 53:3026-32. 2008..Although a significant percentage (25%) of pancreatic cancers demonstrate amplification of the HER2 gene, we find no association of HER2 gene amplification or chromosome 17 hyperploidy with poorer survival... - A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinomaCathy Eng
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
Am J Clin Oncol 27:565-9. 2004..Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma... - Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Clin Oncol 20:4313-8. 2002..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients... - Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasmaRobert A Parise
Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Biomedical Science Tower, E-1040, 200 Lothrop Street, Pittsburgh, PA 15213, USA
J Chromatogr B Analyt Technol Biomed Life Sci 791:39-44. 2003..We believe that this LC-MS assay should be an important tool for future pharmacokinetic studies of imatinib... - Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancerRamesh K Ramanathan
UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 562, Pittsburgh, PA 15232, USA
Cancer Immunol Immunother 54:254-64. 2005..Further evaluation is warranted to examine the effect on disease-free survival and overall survival, especially in early disease and in the absence of immunosuppressive standard therapy... - Multimodality treatment in a case of primary cardiac lymphomaShelly S Lo
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
Clin Lymphoma 4:112-4. 2003..The patient in this report underwent successful surgical resection of a PCL. We now describe her multimodality treatment including autologous stem cell transplantation which resulted in a 22 month survival... - Mucins in gastrointestinal cancersMichael S Turner
Department of Immunology, University of Pittsburgh School of Medicine, Cancer Center, PA 15261, USA
Cancer Chemother Biol Response Modif 21:259-74. 2003..This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future... - Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto
University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
J Clin Oncol 21:2664-72. 2003..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population... - Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
J Clin Oncol 21:2059-69. 2003..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)... - Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons
Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
J Clin Oncol 26:570-6. 2008.... - Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan
Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
J Clin Oncol 26:563-9. 2008..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)... - Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Epidemiol Biomarkers Prev 14:1402-10. 2005..The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer... - Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107Axel Grothey
Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 26:183-9. 2008..As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response... - Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
Clin Cancer Res 13:4832-9. 2007..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function... - Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster
Cancer Institute, New York University Medical Center, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
Clin Colorectal Cancer 5:257-62. 2005..The distinct mechanisms of action and patterns of resistance displayed by pemetrexed and irinotecan make them attractive agents for combination therapy... - Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignanciesXueyu Chen
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 221A, 610 University Ave, Toronto, ON, Canada, M5G 2M9
Cancer Chemother Pharmacol 55:237-43. 2005.... - Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup TrialRichard M Goldberg
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
J Clin Oncol 24:3347-53. 2006..High rates of grade > or = 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4... - Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 24:5201-6. 2006..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma... - Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster
New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
J Clin Oncol 26:3523-9. 2008..To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC)... - Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow
Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
Semin Oncol 30:14-9. 2003.... - Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto
Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
Semin Oncol 30:20-5. 2003..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min... - Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancerAmanda C Ashley
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 110:670-7. 2007..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741... - Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold
City of Hope Comprehensive Cancer Center, Duarte, California, USA
Clin Cancer Res 13:3660-6. 2007..To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population... - Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 25:3469-74. 2007..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach... - The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker
Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA
J Lab Clin Med 147:83-90. 2006..Furthermore, PX-12 decreases plasma VEGF levels that may contribute to the antitumor activity of PX-12... - Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium TrialY Yen
Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
Am J Clin Oncol 31:317-22. 2008..Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin...